Overview

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.
Phase:
PHASE3
Details
Lead Sponsor:
AstraZeneca